This retrospective analysis of data from clinical trials in metastatic urothelial carcinoma (mUC) was conducted to determine baseline patient characteristics associated with long-term survival (LTS) following treatment with immune checkpoint inhibitors.
Data for this analysis were from patients with platinum-refractory mUC who received durvalumab or durvalumab plus tremelimumab in phase 1/2 studies. The primary outcome measure was LTS. Patients were categorised as overall survival (OS) ≥ 2 years (from first dose) or OS < 2 years. A univariable analysis assessed independent associations with LTS and multivariable logistic regression was employed including each variable with P ≤ 0.05 as covariates.
Among 360 patients, 88 (24.4%) had OS ≥ 2 years and 272 (75.6%) had OS < 2 years. In univariable analysis, several baseline characteristics and laboratory measurements were associated with LTS including sex, ECOG PS, PD-L1 expression, prior surgery, time from initial diagnosis, lymph node-only involvement, visceral disease, haemoglobin level, absolute neutrophil count, neutrophil-lymphocyte ratio and lactate dehydrogenase level. In multivariable analysis, LTS was significantly associated with ECOG PS, PD-L1 expression, haemoglobin level and absolute neutrophil count.
Several baseline clinical characteristics and laboratory measurements were associated with LTS for patients with platinum-refractory mUC treated with durvalumab or durvalumab plus tremelimumab.
BMC cancer. 2023 Sep 29*** epublish ***
Marie Alt, Carlos Stecca, Yian Lin, Gbenga Kazeem, Erik T Goluboff, Srikala S Sridhar
Princess Margaret Cancer Centre, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada., AstraZeneca, San Francisco, CA, USA., AstraZeneca, Cambridge, UK., AstraZeneca, Gaithersburg, MD, USA., Princess Margaret Cancer Centre, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada. .